Ligand-Activated Peroxisome Proliferator-Activated Receptor β/δ Modulates Human Endometrial Cancer Cell Survival

Hormones and Cancer

Volumn 4, Issue 6, 2013, Pages 358-370

  Ma, J J ^a,b   Monsivais, D ^a   Dyson, M T ^a   Coon, J S ^a   Malpani, S ^a   Ono, M ^a   Zhao, H ^a   Xin, H ^a   Pavone, M E ^a   Kim, J J ^a   Chakravarti, D ^a   Bulun, S E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENDOMETRIUM CANCER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

APOPTOSIS; BETA CATENIN; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MOLECULAR TARGETED THERAPY; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; THIAZOLES;

EID: 84887402155     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-013-0157-7     Document Type: Article

References (44)

1. Wright JD, Barrena Medel NI, Sehouli J, Fujiwara K, Herzog TJ (2012) Contemporary management of endometrial cancer. Lancet 379: 1352-1360.
2. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.
3. Nout RA, Smit VT, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ et al (2010) Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 375: 816-823.
4. Slomovitz BM, Coleman RL (2012) The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res 18: 5856-5864.
5. Panigrahy D, Kaipainen A, Kieran MW, Huang S (2008) PPARs: a double-edged sword in cancer therapy? PPAR Res 2008: 350351.
6. Lee CH, Olson P, Evans RM (2003) Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144: 2201-2207.
7. Burdick AD, Kim DJ, Peraza MA, Gonzalez FJ, Peters JM (2006) The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation. Cell Signal 18: 9-20.
8. Peters JM, Shah YM, Gonzalez FJ (2012) The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer 12: 181-195.
9. Mangelsdorf DJ, Evans RM (1995) The RXR heterodimers and orphan receptors. Cell 83: 841-850.
10. Tong BJ, Tan J, Tajeda L, Das SK, Chapman JA et al (2000) Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma. Neoplasia 2: 483-490.
11. Michalik L, Desvergne B, Wahli W (2004) Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 4: 61-70.
12. Youssef J, Badr M (2011) Peroxisome proliferator-activated receptors and cancer: challenges and opportunities. Br J Pharmacol 164: 68-82.
13. Schug TT, Berry DC, Shaw NS, Travis SN, Noy N (2007) Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 129: 723-733.
14. Rieck M, Meissner W, Ries S, Muller-Brusselbach S, Muller R (2008) Ligand-mediated regulation of peroxisome proliferator-activated receptor (PPAR) beta/delta: a comparative analysis of PPAR-selective agonists and all-trans retinoic acid. Mol Pharmacol 74: 1269-1277.
15. Cheng YH, Utsunomiya H, Pavone ME, Yin P, Bulun SE (2011) Retinoic acid inhibits endometrial cancer cell growth via multiple genomic mechanisms. J Mol Endocrinol 46: 139-153.
16. Pelton P (2006) GW-501516 GlaxoSmithKline/ligand. Curr Opin Investig Drugs 7: 360-370.
17. Sznaidman ML, Haffner CD, Maloney PR, Fivush A, Chao E et al (2003) Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)-synthesis and biological activity. Bioorg Med Chem Lett 13: 1517-1521.
18. Palkar PS, Borland MG, Naruhn S, Ferry CH, Lee C et al (2010) Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-beta/delta antagonist GSK3787. Mol Pharmacol 78: 419-430.
19. Bissonnette RP, Brunner T, Lazarchik SB, Yoo NJ, Boehm MF et al (1995) 9-cis retinoic acid inhibition of activation-induced apoptosis is mediated via regulation of fas ligand and requires retinoic acid receptor and retinoid X receptor activation. Mol Cell Biol 15: 5576-5585.
20. Spinella MJ, Kitareewan S, Mellado B, Sekula D, Khoo KS et al (1998) Specific retinoid receptors cooperate to signal growth suppression and maturation of human embryonal carcinoma cells. Oncogene 16: 3471-3480.
21. Heinaniemi M, Uski JO, Degenhardt T, Carlberg C (2007) Meta-analysis of primary target genes of peroxisome proliferator-activated receptors. Genome Biol 8: R147.
22. Mahony S, Mazzoni EO, McCuine S, Young RA, Wichterle H et al (2011) Ligand-dependent dynamics of retinoic acid receptor binding during early neurogenesis. Genome Biol 12: R2.
23. Di-Poi N, Tan NS, Michalik L, Wahli W, Desvergne B (2002) Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol Cell 10: 721-733.
24. Chalecka-Franaszek E, Chuang DM (1999) Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A 96: 8745-8750.
25. Noble W, Planel E, Zehr C, Olm V, Meyerson J et al (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A 102: 6990-6995.
26. Berger J, Leibowitz MD, Doebber TW, Elbrecht A, Zhang B et al (1999) Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem 274: 6718-6725.
27. Michalik L, Desvergne B, Tan NS, Basu-Modak S, Escher P et al (2001) Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice. J Cell Biol 154: 799-814.
28. Peters JM, Lee SS, Li W, Ward JM, Gavrilova O et al (2000) Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol 20: 5119-5128.
29. Hollingshead HE, Killins RL, Borland MG, Girroir EE, Billin AN et al (2007) Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands do not potentiate growth of human cancer cell lines. Carcinogenesis 28: 2641-2649.
30. Fukumoto K, Yano Y, Virgona N, Hagiwara H, Sato H et al (2005) Peroxisome proliferator-activated receptor delta as a molecular target to regulate lung cancer cell growth. FEBS Lett 579: 3829-3836.
31. Peters JM, Gonzalez FJ (2009) Sorting out the functional role(s) of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in cell proliferation and cancer. Biochim Biophys Acta 1796: 230-241.
32. Kim DJ, Bility MT, Billin AN, Willson TM, Gonzalez FJ et al (2006) PPARbeta/delta selectively induces differentiation and inhibits cell proliferation. Cell Death Differ 13: 53-60.
33. Marin HE, Peraza MA, Billin AN, Willson TM, Ward JM et al (2006) Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis. Cancer Res 66: 4394-4401.
34. Burdick AD, Bility MT, Girroir EE, Billin AN, Willson TM et al (2007) Ligand activation of peroxisome proliferator-activated receptor-beta/delta(PPARbeta/delta) inhibits cell growth of human N/TERT-1 keratinocytes. Cell Signal 19: 1163-1171.
35. Frame S, Cohen P (2001) GSK3 takes centre stage more than 20 years after its discovery. Biochem J 359: 1-16.
36. Woodgett JR (1990) Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 9: 2431-2438.
37. Fung TK, Gandillet A, So CW (2012) Selective treatment of mixed-lineage leukemia leukemic stem cells through targeting glycogen synthase kinase 3 and the canonical Wnt/beta-catenin pathway. Curr Opin Hematol 19: 280-286.
38. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785-789.
39. Mishra R (2010) Glycogen synthase kinase 3 beta: can it be a target for oral cancer. Mol Cancer 9: 144.
40. Luo J (2009) Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett 273: 194-200.
41. Muyllaert D, Kremer A, Jaworski T, Borghgraef P, Devijver H et al (2008) Glycogen synthase kinase-3beta, or a link between amyloid and tau pathology? Genes Brain Behav 7(Suppl 1): 57-66.
42. Grimes CA, Jope RS (2001) The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65: 391-426.
43. MacDonald BT, Tamai K, He X (2009) Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17: 9-26.
44. Rowe MK, Chuang DM (2004) Lithium neuroprotection: molecular mechanisms and clinical implications. Expert Rev Mol Med 6: 1-18.